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Dyslipidemia: Treatment  
in Statin – Intolerant Patients
Ioannis Skoumas, MD
A b s t r A c t
Statins are the mainstay of lipid-lowering therapy because of their well-established 
efficacy for reducing cardiovascular disease mortality and morbidity in various high 
risk populations. However, certain patients cannot avail themselves of these benefi-
cial effects due to intolerance in these agents. Statin-induced myopathy is by far the 
most common side-effect. A less common side-effect of statin therapy is hepatic tox-
icity. Intolerance to statins is frequently encountered in clinical practice, mostly due 
to muscular symptoms and/or elevation of hepatic aminotransferases, which overall 
constitute approximately two-thirds of reported adverse events during statin therapy. 
The first step in handling intolerant patients is to rule out any secondary causes of 
myopathy or liver toxicity. The second step is to determine whether the adverse effects 
are indeed related to statin therapy by statin dechallenge and rechallenge. Another 
option is to restart therapy with the same statin at a lower dosage or to switch to an-
other statin with different pathways of metabolism. If the symptoms recur, different 
approaches should be considered, such as unconventional dosing (every other-day or 
weekly administration) of statins with longer half-life. Another option in patients who 
cannot tolerate statins is the use of non-statin lowering drugs, such as ezetimibe, bile 
acids sequestrants (colesevelam) and fibrates, alone or in combination. Concerning 
low-risk individuals, the use of herbal supplements effective in reducing LDL choles-
terol may be considered.
I n t r o d u c t I o n
The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, 
or statins, are the mainstay of lipid-lowering therapy because of their well-established 
efficacy for reducing cardiovascular disease (CVD) morbidity and mortality in various 
high risk populations.1 In general, statin therapy is considered to be safe; however, 
it may be associated with rare occurrences of serious adverse events.2 Nevertheless, 
a significant proportion of subjects taking these drugs may experience some degree 
of intolerance. In particular, statin-induced myopathy (SIM) is by far the most com-
mon side effect. A less common side effect of statin therapy is the increase of serum 
aminotransferase levels, which is considered the manifestation of hepatic toxicity.3 
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c l I n I c A l  A s p e c t s  o f  s t A t I n -
A s s o c I A t e d  A d v e r s e  e f f e c t s
The incidence of adverse events during statin therapy has 
been evaluated by several studies. In a meta-analysis of 18 
primary and secondary prevention placebo-controlled trials, 
involving over 70,000 subjects, the number needed to harm 
(NNH) for any adverse event with statins was 197 and the 
number needed to treat (NNT) to prevent one cardiovascular 
event was 27.4 Thus, treating 1,000 patients would prevent 
37 cardiovascular events and cause 5 adverse events. In this 
analysis, serious adverse events, such as elevated values of 
creatine kinase (CK), reaching 10 times the upper limit of 
normal (ULN), or rhabdomyolysis, are rare and have a NNH 
of 3,400. Rhabdomyolysis alone was extremely rare with an 
NNH of 7,428. Another meta-analysis of 83,858 patients treated 
with statins, revealed a low incidence of myositis (0.11%) or 
rhabdomyolysis (0.016%), with no significant increase in statin-
treated compared with placebo-treated patients.5 However, it 
must be noted that the SIM in real-world clinical practice is 
often much higher than that reported in clinical trials. One 
likely explanation for this discrepancy is the underestimation 
of the rate of myopathy in clinical trials, because patients at 
increased risk for statin-induced adverse effects tend to be 
excluded from the study and the presence of muscle symptoms 
or increases in CK during the run-in phase of trials may exclude 
these subjects from randomization.6 On the other hand, a great 
number of patients in clinical practices have many other severe 
comorbidities and may not be as healthy as those enrolled in 
clinical trials. 
To obtain data that are representative of clinical practice, 
it may be helpful to examine databases from cohort studies. 
One such cohort study is the Prediction of Muscular Risk in 
Observational Conditions (PRIMO).7 In the PRIMO study, 
over 7,900 hyperlipidemic patients treated with high-dose statin 
therapy were enrolled in a 12-month, prospective observational 
follow-up. Muscle symptoms were reported in 11% of patients. 
This figure has been confirmed by others,8 and therefore in the 
real world, SIM may affect 10%–15% of statin users. 
The clinical presentation of statin myopathy varies from 
mild fatigue to rhabdomyolysis requiring hospitalization. The 
most frequently reported symptoms include myalgia, fatigue, 
weakness, generalized aching, and low back or proximal muscle 
pain.9,10 There have been less frequent complaints of tendon 
pain and nocturnal muscle cramps.10 According to well accepted 
definitions, myalgia is defined as muscular symptoms without 
CK elevations, myositis refers to muscle symptoms with CK 
elevation, and rhabdomyolysis is defined as muscle symptoms 
with marked CK elevations (>10 times ULN) with an elevated 
plasma creatinine and the occasional presence of brown urine.11 
The relationship between initiation of statin treatment and 
onset of symptoms is widely variable, as is the time between 
cessation of statin treatment and the resolution of symptoms. 
In the PRIMO study the median time of onset of muscle 
symptoms was 1 month following initiation of statin therapy or 
titration to a higher dosage. In another study that used 2 large 
UK primary care databases including a population of about 5 
million people with a follow-up period over 10 years, for many 
patients, it was reported that most SIM cases occurred within 
the first 12 weeks of statin exposure, although few ones could 
be seen up to 52 weeks of treatment.12
SIM does not appear to be related to statin dosage. In a 
review of several atorvastatin trials, treatment-related myalgia 
occurred at a similar rate of 1.4% and 1.5% in subjects receiv-
ing 10 or 80 mg of atorvastatin compared with a rate of 0.7% 
with placebo.13 A retrospective analysis of safety from the 
PROVE-IT trial also suggested that statin adverse effects are 
not related to low density lipoprotein (LDL) level.14 In fact, 
muscular and hepatic side effects were found to occur at the 
same rate across all on-treatment LDL-cholesterol (LDL-C) 
levels, including very low levels of 40 mg/dL. This phenomenon 
has been confirmed in a recent meta-analysis comparing differ-
ent statin doses and on-treatment LDL-C levels.15 Myopathy in 
the elderly can produce a much greater functional impairment 
than in younger patients and this should be taken into account 
when prescribing lipid-lowering therapies in these patients, 
particularly when life expectancy is not long enough.
The other statin-associated adverse effect, the hepatic 
biochemical abnormality, is the asymptomatic elevation of 
aspartate aminotransferase (AST) and alanine aminotrans-
ferase (ALT), which appears to be a class effect of statins and is 
characterized by liver enzyme elevation in the absence of clear 
hepatoxicity.3,9 This side effect could be well interpreted ac-
cording to Hy’s rule, which states that serum bilirubin twice the 
ULN, with ALT more than three times the ULN, with all other 
causes of liver dysfunction excluded, indicates drug-related 
hepatotoxicity. This has been also defined as ‘transaminitis’. 
This condition may take several months to develop and is usu-
ally transient with full resolution following withdrawal of the 
drug. The isolated elevations in gamma-glutamyl transferase 
(GGT) due to statins is rare.16 The occurrence of aminotrans-
ferase elevation during statin therapy ranges from 1%–3%,17,18 
appears to be dose related,19,20 and may be related to bioavail-
ability. In a recent meta-analysis,15 the frequency of a persistent 
elevation of ALT (3 times ULN) for atorvastatin 80 mg and 
simvastatin 80 mg was up to 5 times compared to atorvastatin 
10 mg and simvastatin 20–40 mg (0.2% vs 1%). Hepatocellular 
injury seen during statin therapy seemed to be an early side 
effect, occurred on average 4 weeks (range 1 to 8 weeks) after 
initiation of treatment but resolved within 4 weeks of statin 
therapy discontinuation.21
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p A t h o p h y s I o l o g y  o f  s t A t I n  –
A s s o c I A t e d  A d v e r s e  e f f e c t s
Although the underlying mechanisms of statin–associated 
adverse effects have not been determined, several hypoth-
eses have been proposed. Cholesterol plays a key role in cell 
membrane fluidity, and therefore it has been suggested that 
cholesterol reduction with statins may perturb the integrity 
of the plasma membrane of myocytes.22 Another hypothesis 
is based on the reduction of ubiquinone or coenzyme Q10 
(CoQ10), due to the block of cholesterol synthesis by statins 
early in its metabolic pathway.23 A reduction in this coenzyme 
could result in an abnormal mitochondrial respiratory function 
due to the key role that plays in the electron transport chain. 
However, several lines of evidence make these explanations 
unlikely, because when cholesterol is decreased by inhibiting 
squalene synthetase, no increase in myotoxicity is observed.24 On 
the other hand, human and animal studies have demonstrated 
that statin treatment may reduce serum CoQ10 levels; however 
myocyte CoQ10 levels have not been consistently decreased 
with statin treatment.25 
Another proposed mechanism of myotoxicity is depletion 
of isoprenoids that control the rate of myofiber apoptosis.26 
Isoprenoids are lipids produced by HMG-CoA reductase path-
way.27 Isoprenoids are linked to proteins by either farnesylation 
or geranylgeranylation. According to this theory, statins block 
the production of farnesyl pyrophosphate and this prevents 
the prenylation of GTP-binding proteins Ras, Rac, and Rho. 
There is evidence that reduction of the prenylated forms of 
these proteins leads to increased cytosolic calcium, which in 
turn activates a cascade of events leading to the activation of 
proteolytic enzymes caspase-3 and caspase-9, which have a 
central role in cell death.27 The apoptosis theory is supported 
by studies on vascular smooth muscle cells, which demonstrated 
that statin-induced apoptosis can be prevented with isoprenoids 
supplementation but not CoQ10.28
Finally another explanation of statin-myopathy is the ob-
servation that statins impair intracellular calcium homeostasis 
by interfering with the mitochondrial respiratory chain and by 
affecting ryanodine receptor one (RyR1), which pumps cal-
cium into the cytoplasm. Increased cytoplasmic calcium levels 
have been shown to cause cramps, myalgias and apoptosis.29,30 
Recently, genetic risk factors for statin myopathy have been 
identified. A strong association has been found between treat-
ment with a high-dose statin regimen and genetic variants that 
affect statin blood levels, in the Effectiveness of Additional 
Reductions in Cholesterol and Homocysteine (SEARCH) 
trial.31 In this trial, a genome-wide analysis demonstrated that a 
single nucleotide polymorphism within intron 11 of SLCO1B1 
on chromosome 12 was strongly associated with myopathy. 
The gene SLCO1B1 encodes the organic anion transporting 
polypeptide responsible for hepatic uptake of statins. In the 
SEARCH trial, the majority (60%) of myopathy cases were 
associated with SLCO1B1 variants. 
The mechanism by which statins may induce hepatocellular 
injury, the other major side effect, is unclear. The depletion 
of mevalonate or one of its sterol metabolites caused by the 
inhibition of 3-hydroxyl, 3-methyl-glutaryl-CoA reductase 
(HMG-CoA) enzyme may be responsible for the elevated 
liver enzymes.32 The type of metabolism of statins seems to be 
related with the hepatotoxicity of these agents. Simvastatin, 
lovastatin, fluvastatin and atorvastatin are indeed metabolized 
through cytochrome P450, while pravastatin, rosuvastatin and 
pitavastatin follow another metabolic pathway. Statins differ 
as far as lipophilicity is concerned. The less lipophilic statins, 
such as pravastatin, rosuvastatin, atorvastatin and fluvastatin 
augment the risk of aminotransferase elevation, compared to 
the other more lipophilic ones, although the reverse effect is 
observed regarding the CK elevation.11,12 A clear explanation 
for this is not available even though one could implicate the 
hepatic organic anion transport protein (OATP or SLCO1B1) 
that plays an important role in facilitating the penetration of 
statin into the hepatocytes. It has been reported that genetic 
variations in SLCO1B1 have a larger effect on the area under 
the plasma concentration-time curve of atorvastatin than that 
observed with the more hydrophilic rosuvastatin.33
The natural history of elevated liver enzymes due to the 
long-term use of statins is poorly understood. However, it is 
recognized that in some individuals, this elevation is transient 
and may be physiological rather than pathological and that some 
patients display ‘adaptation’, where liver enzymes stabilize/
normalize if the drug is not withdrawn.34 There are no studies 
that correlate hepatic histology with elevations in liver enzymes 
to differentiate between true hepatotoxicity and an adaptive 
process. The US National Lipid Association’s (NLA) Safety 
Assessment Task Force concluded in 2006 that there was no 
evidence of a relationship between elevated transaminases, 
statin therapy and risk of significant liver injury.3 Furthermore, 
they also concluded that routine monitoring of liver enzymes 
did not identify those individuals at risk of developing idiosyn-
cratic liver failure. In addition, recent evidence suggests that 
moderate elevation of transaminases should not contraindicate 
the initiation of statin therapy.
A post-hoc analysis of the secondary prevention Greek Ator-
vastatin and Coronary Heart Disease Evaluation (GREACE) 
study,35 assessed the cardiovascular and liver outcomes in 
a total of 437 patients presenting moderately elevated liver 
enzymes (>3 times ULN) at enrollment, suggested that they 
are possibly associated with non-alcoholic fatty liver disease. 
Two hundred twenty seven of these individuals who were 
treated with a statin (mainly atorvastatin, 24 mg per day) had 
substantial improvement in liver tests (p = 0.0001), whereas the 
210 individuals not treated with a statin had further increases 
of liver enzyme concentrations during the 3-year follow-up of 
this study. Furthermore, patients with abnormal liver tests who 
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received a statin, experienced fewer cardiovascular events in 
comparison to patients with abnormal liver tests who did not 
receive one (68% relative risk reduction, p = 0.0001). Interest-
ingly, this cardiovascular benefit was greater (P = 0.0074) in 
patients with abnormal liver tests than it was in patients with 
normal liver enzymes. 
The most frequently seen histological appearance of statin-
induced liver injury is inflammation of the portal tracts with 
mild piecemeal necrosis and focal periportal fibrosis.36 As 
serious hepatotoxicity caused by statins is rare, these findings 
are seldom seen. The FDA’s Adverse Event Reporting System 
database until 2004, reported a rate of 0.69 cases of liver fail-
ure/hepatitis per million statin prescriptions, a figure similar 
to that reported for liver failure/hepatitis in the general adult 
population.3 Analysis of an administrative database showed 6.1 
to 12.8 hepatic events per 10,000 person-years of hospitalized 
patients on statins.38 None were hospitalized within 6 months 
of starting their statin. Furthermore, only 1 of the 51741 pa-
tients who underwent liver transplantation between 1990 and 
2002 was taking a marketed statin.17,37 Adverse drug reaction 
reports from the UK Committee on Safety of Medicines show 
4 deaths caused by atorvastatin-induced hepatotoxicity over 
an eight-year period (0.5 deaths per annum).38 In addition, 
there are also reports of rosuvastatin, fluvastatin, and atorv-
astatin inducing or revealing autoimmune disease, including 
autoimmune hepatitis. This is an extremely rare effect and 
there is evidence that the hepatic effect may be reversible 
when the drug is withdrawn.39-41 Finally, in very rare circum-
stances, statin therapy may cause liver failure.42,43 Overall, 
the long-term hepatic safety of statins is reassuring. In fact, it 
has been reported that 24 million patient years of treatment 
with lovastatin reveal a rate of acute liver failure of 1 per 1.14 
million patient-treatment years, which is similar to the rate of 
idiopathic acute liver failure.36 Nevertheless, the potential for 
statin-associated severe liver injury makes the monitoring of 
liver enzymes during this treatment important to recognize 
drug-induced liver injury as early as possible.
M A n A g I n g  s t A t I n  I n t o l e r A n t 
p A t I e n t s
The first step is to rule out any possible conditions that 
increase the risk of statin-induced adverse effects. The most 
common of these conditions are reported in Table 1.
A complete examination should exclude related conditions 
such as hypothyroidism, rheumatological disorders, neuro-
muscular diseases, and depression. A recent study also noted 
that over 90% of vitamin D-deficient patients with myalgias 
on statins had resolution of their symptoms after 50,000 U/
wk of vitamin D for 12 weeks.44 Thus, measurements of CK, 
TSH, and vitamin D should be carried out if not recently done. 
Under routine clinical settings, a baseline CK is not necessary 
but is an option if the patient is at higher risk for statin-induced 
myopathy.1 In asymptomatic patients, the measurement of CK 
is not cost effective.45 High asymptomatic pre-treatment levels 
of CK should not discourage the initiation of statin treatment, 
provided that CK levels are <5 × ULN.46 Recommendations 
to manage muscle related symptoms in patients receiving 
statin, have been proposed by the National Lipid Association 
Statin Safety Task Force 4 (Fig. 1). According with these 
recommendations, in patients with moderate symptoms and 
without significant CK elevation (<5 × ULN), progress can be 
followed clinically. If the muscular symptoms are severe and in 
those with CK elevated more than 5 × ULN, statins should be 
stopped. Once CK is normalized and the muscular symptoms 
have been resolved, patients should be rechallenged with the 
same or other statin at the same or lower dosage. Otherwise, 
different approaches can be considered (Table 2). Guidelines 
have also been issued to manage liver intolerance to statins 
(Fig. 2).3,16,17
An elevation of baseline hepatic transaminases <3 times 
ULN is not a contraindication to starting statin therapy. Non-
alcoholic fatty liver disease with transaminase levels fluctuating 
between 1.5 and 3 × ULN is present in many patients with 
diabetes, metabolic syndrome, or obesity.19 If there are no other 
etiologies responsible for the transaminase elevation, a low-
to-moderate statin dose can be started with close monitoring 
alanine aminotransferase levels. The best time to recheck liver 
biochemistry values is not so clear. In two trials, the HPS and 
the AFCAPS/TexCAPS trial, the time to recheck liver profile 
was 3 and 2 weeks, respectively, with normalization of the values 
in more than 70% of the cases.43 If the aminotransferase levels 
are >3 × ULN, it is recommended to stop the treatment and 
reassess liver tests. Although the time between the normaliza-
tion of liver enzymes and the restart of medical hypolipidemic 
therapy is not clear, patient can continue taking the same statin 
and scheme or the same or another statin at lower dosage.16,17 
Conversely, when the elevation in aminotransferase levels is 
persistent after statin withdrawal or reoccurs after a statin re-
challenge, other options should be considered. Several authors 
have recommended using low-dose statin treatment because of 
the possible greater incidence of liver enzyme elevations with 
higher doses. It has also been proposed that liver biochemistry 
monitoring should be performed every month for the first 3 to 
4 months and 4 times a year thereafter. Additionally, the use 
of statins, which are not metabolized by the liver or the use of 
nonstatin compounds can be considered. A detailed evaluation 
of the different options to manage statin intolerant patients 
is reported below.
s w I t c h I n g  t o  A n o t h e r  s t A t I n
Once symptoms, CK and aminotransferase levels return 
to baseline, a different statin with less risk for hepatotoxicity 
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and myopathy, may be considered. The criteria to select the 
new statin are not well-defined. One possibility could be to 
change from a mildly to a highly lipophilic statin. It has been 
demonstrated that the less lipophilic statins (pravastatin, ro-
suvastatin, atorvastatin, fluvastatin) increased the relative risk 
of aminotransferase elevation compared to the more lipophilic 
ones (lovastatin, simvastatin, cerivastatin).47 On the other hand, 
a change from a P450-dependent to a non-P450-dependent 
statin, such as fluvastatin or rosuvastatin, has been observed to 
decrease the risk of CK elevation. Hansen et al, in a follow-up 
of 45 patients with confirmed SIM, found that 43% of patients 
tolerated the new statin without reporting symptoms.48 
A l t e r n A t e - d A y  o r  w e e K l y  s t A t I n 
d o s I n g
Although this approach is a non-approved statin dosing 
regimen in patients with SIM, it has been based on the concept 
that statins with a longer half-life may maintain their hypolipi-
demic effect over a longer period of time. Atorvastatin has a 
mean terminal half-life of 14 hours and generates two active 
(orthohydroxy and parahydroxy) metabolites, which contribute 
to 70% of its HMG-CoA reductase activity and have a half-life 
of 20–30 hours.49 The other statin that exhibits a half-life of 
19 hours is rosuvastatin. A double-blind, placebo-controlled 
trial of 35 patients receiving atorvastatin, 10 mg daily versus 
alternate day regimen, showed LDL cholesterol reductions of 
tAble 1. Potential risk factors for statin-induced myopathy (SIM) and hepatic side effects of statins
statin-induced myopathy hepatic toxicity
endogenous risks Acute viral diseases
Frailty and low body mass index Alcohol-associated liver diseases
Advanced age (>80 y) Advanced chronic liver diseases
Multisystem disease Mildly lipophilic statins 
Renal dysfunction Genetic factors (CYP450 isoenzymes)
Hepatic dysfunction
Hypothyroidism 
Metabolic muscle diseases:
Carnitine palmityl transferase II deficiency
McArdle disease (myophosphorylase deficiency)
Myoadenylate deaminase deficiency
Family history of muscular symptoms
Personal history of elevated creatinine kinase or muscular symptoms
Genetic factors (CYP450 variants, drug transporter variants)
exogenous risks
Heavy alcohol consumption 
High physical activity 
Major surgery
Drugs affecting statin metabolism 
(gemfibrozil, nicotinic acid, cyclosporin, amiodarone, macrolides 
antibiotics, verapamil, diltiazem, systemic use of azole antifungals, 
warfarin, digoxin, colchicine, protease inhibitors) 
Consuming >1L of grapefruit juice per day 
Genetic factors (CYP450 variants, drug transporter variants)
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and Thursday) for a time longer than 3 weeks, at doses of 5 
and 10 mg, which produced a significant 26% reduction of 
LDL-C from baseline, in patients (mean age 62 ± 8 years) with 
SIM related to other lipid-lowering therapy (other statins or 
niacin or fibrate or combinations of these). Rosuvastatin was 
well tolerated by 80% of patients.52 Once weekly rosuvastatin 
5-20 mg, resulted in a mean LDL cholesterol reduction of 29% 
among 8 intolerant patients without any incidence of SIM. 53 
In another study with similar dosing protocol, Ruisinger 
et al enrolled 50 patients with a previous statin adverse event. 
Rosuvastatin once per week was tolerated by 37 (74%) of the 
50 study participants, with doses ranging from 2.5 to 20 mg 
a week (mean 10 mg).54 Patients tolerating the once-a-week 
regimen experienced a 17% reduction in total cholesterol, 
23% reduction in LDL-C, 12% reduction in triglycerides, 
and a 5% increase in high density lipoprotein cholesterol (all 
p=0.001), during a mean follow-up of 4 months. The lower 
overall plasma concentrations from the less frequent dosing 
and the psychological factor of receiving only a once-weekly 
dose may be possible explanations for tolerance.
Although the alternate-day statin dose administration has 
tAble 2. Managing statin intolerant patients. 
 • Switching to another statin with different metabolism
 • Selection of a statin with longer half-life and an alternate-day 
or weekly dosage regimen 
 • Combination therapy with infrequent statin dosing and 
ezetimibe
 • Nonstatin lipid lowering drugs
 • Nutraceuticals and specific diets
 • LDL apheresis 
38% and 35%, respectively, without any myopathy.50 Out of 
51 statin intolerant patients, who received rosuvastatin, 5 or 
10 mg on alternate days, 72.5% (37 out of 51) of patients were 
able to tolerate this regimen without recurrence of myalgia 
for 4 months. Mean LDL-C decreased by 34.5% (p<0.001) 
in patients who tolerated the regimen and 50% achieved the 
LDL-C goal.51 
Gadarla et al utilized rosuvastatin twice weekly (Monday 
fIgure 1. Algorithm for management of statin induced myopathy. BAS = bile acid sequestrants, CK = creatine kinase; ULN = upper 
limit of normal.
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been demonstrated to be feasible and effective, it has some 
limitations. First of all, this regimen allows a lower LDL-C 
reduction (up to 10%–15% less) compared to the every-day 
regimen. This must be carefully considered in light of the 
ideal LDL-C target for each patient. Second, these dosing 
regimens have not been proven to reduce cardiovascular 
events. Therefore, they must be considered as an alternative 
treatment in well-selected patients such as those who did not 
tolerate more than one statin, even at lower dosage, and may 
otherwise go without any benefits from statin therapy. Thus, 
nondaily rosuvastatin and atorvastatin seem tolerable and 
may help lower LDL cholesterol levels in patients with statin 
intolerance.
c o M b I n A t I o n  t h e r A p y  w I t h 
I n f r e q u e n t  s t A t I n  d o s I n g
A novel approach to managing statin intolerant patients was 
investigated by Athyros et al.55 The investigators administered 
to 56 statin intolerant patients a combination therapy with a 
statin twice weekly and ezetimibe 10 mg daily. After starting 
ezetimibe 10 mg/day, 10 mg of atorvastatin twice weekly was 
added. The LDL-C was lowered by 34% and 84% of patients 
achieved the NCEP ATP III LDL-goal. 
n o n s t A t I n  l I p I d - l o w e r I n g  d r u g s 
A l o n e  o r  I n  c o M b I n A t I o n 
Non statin lipid -lowing drugs should be considered if the 
patient is unable to take statins because of myopathy. These 
drugs may be used as monotherapy or in combination and 
include bile acid sequestrants (colesevelam), an intestinal 
cholesterol absorption inhibitor (ezetimibe), fibrates and 
niacin. Dosage at 3.75 g/day of colesevelam results in a 15-
19% reduction of LDL-C,56 and 10 mg at ezetimibe is able to 
decrease LDL-C by 15-20%.57 In 27 statin intolerant patients 
the administration of ezetimibe 10 mg daily for 3 months 
was associated with a reduction of total cholesterol (TC) and 
LDL-C of 18% and 26% respectively (p<0.001 for both) 
and 25 out of 27 patients completed the three-month period 
without muscle pain.58 In 66 statin-intolerant hyperlipidemic 
patients the administration of ezetimibe 10 mg daily for 12 
weeks was associated with recurrence of muscle symptoms 
in 24%.59 However, a few instances of myopathy have been 
reported,60 the majority of which occurred in patients previ-
ously intolerant to statins. There are two main concerns with 
ezetimibe treatment. The first is that the majority of patients 
in ezetimibe therapy fail to achieve the LDL-C target and the 
second is that there are no data regarding the clinical benefit 
of this intervention.
Colesevelam has a favorable tolerability and drug interac-
tion profile than cholestyramine and cholestipol. In a retrospec-
tive review Rivers et al61 administered in 16 statin intolerant 
patients with diabetes mellitus and metabolic syndrome the 
combination of ezetimibe (10 mg/day) plus colesevelam (1.875g 
twice daily). The combination therapy was well tolerated and 
resulted in a marked reduction of both LDL-C (42.2%) and 
non-HDL (37.1%).
Another option for statin intolerant patients is fibrates 
which are effective drugs in patients with atherogenic dyslipi-
demia (high triglycerides and low HDL).62 The combination 
of fenofibrate and ezetimibe in patients with mixed hyperlipi-
demia63 reduced the LDL-C by 22%, the non-HDL-C by 31.6% 
and the apoB by 25.2%; additionally the above mentioned 
combination increased the HDL-C by 20.9% and with this 
fIgure 2. Managing the abnormal liver enzymes from statin 
therapy. ULN = upper limit of normal.
TREATMENT IN STATIN-INTOLERANT PATIENTS
67
combination the incidence of muscle symptoms was very low.
Another possible alternative in statin intolerant-patients 
is niacin alone or associated with laropiprant. Niacin has been 
reported to be effective in reducing LDL-C, triglycerides and 
increasing HDL.64,65 At present no data are available in the lit-
erature on the use of nicotinic acid in statin-intolerant patients.
l d l  A p h e r e s I s
This type of LDL-C lowering treatment can be applied in 
coronary patients intolerant to statins (or any other lipid low-
ering drug) whose LDL-C levels remain >5 mmol/L (193 mg/
dL) despite maximum non-statin lipid-lowering medication.66 
d I e t A r y  M A n I p u l A t I o n  A n d  l I p I d 
l o w e r I n g  n u t r A c e u t I c A l s
For dyslipidemic patients who cannot tolerate statins, a 
reasonable approach is a more intensive lipid-lowering dietay 
intervention. This may be obtained by combining dietary 
ingredients with cholesterol-lowering properties, like foods 
low in saturated fat and high in viscous fibers (e.g., oats and 
barley), plant sterols, vegetable protein foods (soy), and nuts 
(e.g., almonds). Jenkins et al evaluated the efficacy of this 
intensive diet versus lovastatin in 46 hyperlipemic adults, 
who were randomly assigned to a diet very low in saturated 
fat (control); the same diet plus lovastatin 20 mg/d (statin); or 
a diet high in plant sterols (1.0 g/1000 kcal), soy protein(21.4 
g/1000 kcal), viscous fibers (9.8 g/1000 kcal), and almonds (14 
g/1000 kcal) (dietary portfolio).67 After four weeks, changes in 
LDL-C were 8.0% (p = 0.002), 30.9% (p = 0.001), and 28.6% 
(p = 0.001), in the control, statin and diets, respectively. It is 
important to note that this intensive diet led to a cholesterol 
reduction that was comparable to that observed with statin. 
Limitation of this intensive diet is the palatability, because only 
40% of participants found this diet acceptable.
An alternative option may be the dietary supplementation 
with nutraceuticals. Among these compounds, the yeast rice is 
of particular interest. Chinese red yeast rice is a dietary sup-
plement made by fermenting the yeast, Monascus purpureus, 
over rice. Monascus yeast produces a family of substances 
called monacolins capable of inhibiting the enzyme HMG-
CoA reductase and also contains unsaturated fatty acids and 
phytosterols.68
Becker et al randomly assigned 62 statin-intolerant dys-
lipidemic patients (baseline LDL-C 163.3 mg/day) to receive 
red yeast rice 1800 mg twice daily or placebo for 24 weeks and 
reported a 22% differential decrease in LDL at 12 weeks and 
12% at 24 weeks.69 Only 2 of the 31 (6.5%) patients on red 
yeast rice could not tolerate this regimen, due to myalgias.
In another study which compared red yeast rice vs pravas-
tatin, 20 (95%) out of 21 statin- intolerant patients were able 
to tolerate without myalgias 2400 mg twice daily, with a 30% 
LDL-C lowering vs 27% in pravastatin group (20 x 2 daily) after 
12 weeks of treatment.70 A more recent retrospective study71 
reported that most (92%) of 25 statin –intolerant patients, 
who underwent treatment with red yeast rice tolerated the 
nutraceutical at a dose of 1200 mg at bed time for more than 
4 weeks, achieving a 21% LDL-C reduction.
Different commercial preparations of red yeast rice (RYR) 
have different concentrations of monacolins, the bioactive in-
gredients69 and the long-term safety of the regular consumption 
of these products is not fully documented. For this reason the 
EAS recommend the utilization of the red yeast rice supple-
ment with a level of evidence B.72
I s  t h e r e  A n y  r o l e  f o r  s p e c I f I c 
t r e A t M e n t s  t o  A t t e n u A t e  s t A t I n 
I n t o l e r A n c e ?
It has been reported that SIM may be due to the statin 
induced reduction of CoQ10. Supplementation of CoQ10 
increases its blood levels, but it is unclear whether this has a 
favorable effect on statin induced myopathy.73 In a successful 
trial with CoQ10 supplementation, in patients with myopathic 
symptoms,74 pain severity decreased by 40% (p<0.001) and pain 
interference with daily activities decreased by 38% (P<0.02) 
in patients who treated with CoQ10. However, these findings 
have not been replicated in larger trials. Therefore, the routine 
use of CoQ10 is not recommended in statin-intolerant patients.
Vitamin deficiency is associated with myalgias and poor 
muscle function.75 This knowledge has led to the exploration 
of the potential benefits of vitamin supplementation in SIM. 
In a recent but small trial with statin-intolerant patients and 
vitamin D levels below 32 mg/ml, the administration of vitamin 
D supplementations for 3 months increased vitamin D levels 
and 92% of patients were free of myalgias.76 These results, 
although interesting, need to be validated by a large double 
blind placebo-controlled trial. Today there is no specific rec-
ommendation for the alleviation of symptoms related to statin 
induced myopathy..
c o n c l u s I o n 
Intolerance to statins is frequently faced in clinical practice. 
This is mostly due to muscular symptoms and/or elevation 
of hepatic aminotransferases, which overall constitute ap-
proximately two-thirds of reported adverse events during statin 
therapy. The first step in handling statin-intolerant patients is 
to rule out any secondary causes of myopathy or liver toxicity. 
The second step is to determine whether the adverse effects 
are indeed related to statin therapy by statin dechallenge and 
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rechallenge. Another option is to restart with the same statin 
at a lower dosage or to switch to another statin with different 
pathways of metabolism. If the symptoms are recurrent, differ-
ent approaches should be considered, such as unconventional 
dosing (every-other-day or weekly administration) of statins 
with longer half-life. Another option in patients who cannot 
tolerate statins is the use of nonstatin lipid-lowering drugs 
(ezetimibe, bile acids sequestrants and fibrates) alone or in 
combination. Concerning low-risk individuals, the use of herbal 
supplements effective in reducing LDL-C can be considered. 
However, the need for randomized trials which directly compare 
lipid-lowering agents, and assess more properly the incidence 
of milder myopathies is mandatory.
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